Recombinant human complement component C2 produced in a human cell line restores the classical complement pathway activity in-vitro: an alternative treatment for C2 deficiency diseases. - Martini PG; Cook LC; Alderucci S; Norton AW; Lundberg DM; Fish SM; Langsetmo K; Jönsson G; Lood C; Gullstrand B; Zaleski KJ; Savioli N; et al. (BMC immunology, 2010)